Pricing Log in Create free account

ProQR Therapeutics N.V. (PRQR) vs Atrium Therapeutics, Inc. (RNA)

ProQR Therapeutics N.V. and Atrium Therapeutics, Inc. are both Biotechnology companies. ProQR Therapeutics N.V. and Atrium Therapeutics, Inc. are of similar size ($190.5M and $185.8M). Atrium Therapeutics, Inc. has the higher net margin (−203.7% vs −228.7%) and the higher return on invested capital (0.00% vs 0.00%). Across the 13 metrics below, Atrium Therapeutics, Inc. leads on 9 and ProQR Therapeutics N.V. on 4.

Valuation

Metric PRQR RNA Biotechnology median
P/E n/m n/m 10.60
P/S 6.92 5.08 9.40
P/B 1.61 0.66 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m 2.03 0.66
EV/Sales 1.06 (4.33) 9.02
Earnings yield (34.07%) (40.03%) (32.88%)
Free cash flow yield (38.66%) (40.71%) (23.13%)

Profitability

Metric PRQR RNA Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin (233.33%) (214.60%) 0.00%
Net margin (228.71%) (203.67%) 0.00%
Free cash flow margin (267.36%) (206.99%) 0.00%
Return on equity (58.29%) 0.00% (51.96%)
Return on assets (31.53%) (40.74%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric PRQR RNA Biotechnology median
Revenue growth (TTM) 19.72% — 6.76%
EPS growth (last fiscal year) (28.57%) — 29.88%
Revenue growth, 5-year CAGR — 22.54% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PRQR RNA Biotechnology median
Debt to equity 0.06 0.00 0.00
Current ratio 3.49 8.73 4.97
Net debt to EBITDA 2.15 9.08 1.01

Dividend

Metric PRQR RNA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric PRQR RNA Biotechnology median
Market cap 190.51m 185.78m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack